Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8dd7a3f96ab370d3939703f0f8430f3a |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-11 |
filingDate |
2004-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2010-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df2f5cf84b86a8c1fe943778df1e8b34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9746c1bcd2dafb39304c9cdad2f0996c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8b302cb4f434f4c31a785a43a40101e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8aa6396b93144e04a7c01f3046314d7d |
publicationDate |
2010-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1697401-B1 |
titleOfInvention |
Tetrapeptide regulating blood glucose level in diabetes mellitus |
abstract |
The invention refers to the field of medicine and can be applied as a substance capable of regulating glucose level while treating and preventing diabetes mellitus. There is proposed a biologically active new tetrapeptide lysyl-glutamyl-aspartyl-tryptophane of general formula Lys-Glu-Asp-Trp-NH2 capable of regulating the glucose level, and pharmacological substance containing an effective amount of tetrapeptide lysyl-glutamyl-aspartyl-tryptophane of the general formula Lys-Glu-Asp-Trp-NH2. There is proposed the method of prevention and/or treatment of the diabetes mellitus, which consists in administering to a patient of the pharmacological substance, containing as an active peptide agent an effective amount of Lys-Glu-Asp-Trp-NH2 tetrapeptide in doses of 0,1 - 30 µg/kg of the body weight at least once a day for a period necessary for attaining a therapeutic effect. |
priorityDate |
2003-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |